Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

Given that more than 40% of Indian adults are struggling with obesity and diabetes, affordable weight-loss drugs are expected ...

We recently compiled a list of the Jim Cramer Discusses 17 Stocks And Blasts Zero Day Options. In this article, we are going ...

Weight-loss medication like Semaglutide and Tirzepatide has seen a rise in demand, causing a boom in sales. This exploding ...

rather than changing diet, to control obesity. Novo Nordisk had hoped its “next generation” weight-loss drug could lead the field, after its shares had struggled to keep pace with Eli Lilly ...

Novo Nordisk’s shares fell sharply on Friday as disappointing results from tests of its latest obesity drug wiped about €90bn off the valuation of Europe’s largest company by market capitalisation.

No surprise that what was described as the first clinical comparative effectiveness study of tirzepatide (Mounjaro, Eli Lilly ... weight and make changes in diet and exercise habits.

Age, race, sex, environmental and lifestyle factors such as physical activity and diet are important determinants ... SERMs such as Evista (raloxifene, Eli Lilly) are used in pre-menopausal ...

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...

Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by joining as a defendant, stating it wants to end the “entitlement” some ...

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...